Achilles Therapeutics PLC saw its American Depositary Receipts (ADRs) soar by an impressive 32%, reflecting renewed investor optimism following the company’s recent announcement of stringent cost-cutting measures. This move, which comes at a time of financial strain for many biotech companies, highlights Achilles’ commitment to securing its financial future while advancing its cutting-edge cancer therapies. […]
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a trailblazer in the field of biotechnology focused on developing novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies, has made a groundbreaking announcement. The U.S. Food and Drug Administration (FDA) has approved AMTAGVI (lifileucel) suspension for intravenous infusion, marking a significant milestone in the treatment of adult patients with unresectable […]
Moderna, Inc. (NASDAQ: MRNA) and Merck (NYSE: MRK), also known as MSD outside the United States and Canada, today revealed follow-up data from their collaborative Phase 2b KEYNOTE-942/mRNA-4157-P201 study. This clinical trial evaluates mRNA-4157 (V940), an innovative individualized neoantigen therapy (INT), in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, for patients with resected high-risk melanoma (stage […]
Moderna and Merck announced that the investigational personalized mRNA cancer vaccine mRNA-4157/V940 in combination with the latter’s lung cancer drug KEYTRUDA (pembrolizumab) has been given breakthrough therapy designation by the US Food and Drug Administration (FDA). The breakthrough therapy designation for the combination is for its use as adjuvant treatment of high-risk melanoma in patients […]
ImmVira said that it has wrapped up the first dosing of its oncolytic virus product – MVR-T3011 intratumoral injection in phase 2 clinical trials both in China and the US. According to the Chinese pharma company, the US phase 2a portion of the study has two parts, of which the first is the evaluation of […]
OncoSec Medical has dosed the first patient in the OMS-104 phase 2 clinical trial, which is evaluating TAVO (tavokinogene telseplasmid) in combination with OPDIVO (nivolumab) as a neoadjuvant therapy for melanoma. TAVO is OncoSec Medical’s intratumoral DNA plasmid-based interleukin-12 (IL-12) therapy, which is intended to be administered using its gene delivery platform (gene electrotransfer). On […]
US biopharma company Soligenix has wrapped up enrolling patients for its phase 3 Fluorescent Light Activated Synthetic Hypericin clinical trial (FLASH clinical trial) for SGX301 (synthetic hypericin) in cutaneous T-cell lymphoma (CTCL). The late-stage study enrolled 169 subjects in the FLASH clinical trial. This was after Soligenix secured positive interim analysis, which included a prospectively […]
In a significant development for melanoma treatment, the European Commission (EC) has granted Novartis approval for its combination therapy of Tafinlar (dabrafenib) and Mekinist (trametinib). This approval is specifically for adjuvant therapy in stage III melanoma patients who are positive for the BRAF V600 mutation and have undergone complete surgical resection. The approval is based […]
